logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Therapeutic Area
    3. Gastroenterology & Hepatology

    Gastroenterology & Hepatology drugs

    FiltersReset Filters
    31 results

    • avastin

      (bevacizumab)
      Genentech, Inc.
      Usage: Avastin is indicated for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and advanced epithelial ovarian or peritoneal cancers, often in combination with other chemotherapy agents.

    • avsola

      (infliximab-axxq)
      Amgen Inc
      Usage: AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining remission in moderately to severely active Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), and other conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.

    • avycaz

      (ceftazidime, avibactam)
      Allergan, Inc.
      Usage: AVYCAZ (ceftazidime and avibactam) is indicated for treating complicated intra-abdominal and urinary tract infections, including pyelonephritis, as well as hospital-acquired and ventilator-associated bacterial pneumonia. It targets susceptible gram-negative bacteria in adult and pediatric patients (≥31 weeks gestational age).

    • barhemsys

      (Amisulpride)
      Acacia Pharma Ltd
      Usage: BARHEMSYS® is indicated for adults to prevent and treat postoperative nausea and vomiting (PONV), either alone or in combination with a different class antiemetic, and for patients who have or have not received prior antiemetic prophylaxis.

    • bonjesta

      (doxylamine succinate and pyridoxine hydrochloride)
      Duchesnay USA, Inc.
      Usage: BONJESTA is indicated for treating nausea and vomiting of pregnancy in women unresponsive to conservative measures. It has not been studied for hyperemesis gravidarum.

    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

    • defitelio

      (defibrotide sodium)
      Jazz Pharmaceuticals, Inc.
      Usage: DEFITELIO is indicated for treating adult and pediatric patients with hepatic veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), accompanied by renal or pulmonary dysfunction after hematopoietic stem-cell transplantation (HSCT).

    • givlaari

      (givosiran sodium)
      Alnylam Pharmaceuticals, Inc.
      Usage: GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).

    • ibsrela

      (tenapanor hydrochloride)
      Ardelyx, Inc.
      Usage: IBSRELA is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

    • motegrity

      (PRUCALOPRIDE)
      Takeda Pharmaceuticals America, Inc.
      Usage: MOTEGRITY® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.